SCHEMBL684015

SCHEMBL684015

CC1CN(Cn2cnc3c2c(=O)n(C)c(=O)n3C)CCN1C(c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
MAPK1 P28482 2/20 0.49
HTR1A P08908 3/20 0.48
CHRM1 P11229 3/20 0.48
DRD2 P14416 3/20 0.48
ADRA1D P25100 3/20 0.48
ADRA1A P35348 3/20 0.48
ADRA1B P35368 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
RXFP1 Q9HBX9 3/20 0.48
ADORA2B P29275 1/20 0.48
HTR7 P34969 1/20 0.46
HTR6 P50406 1/20 0.46
CHRM2 P08172 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HTR2A P28223 1/20 0.45
HTT P42858 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GLA P06280 1/20 0.43
UBE2N P61088 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682838 0.86 HTR2A (0.57) MAPK1ADORA2BHTR2ANPSR1GLA
SCHEMBL684054 0.86 HTR1A (0.62) LMNAMAPK1HTR1ACHRM1DRD2
SCHEMBL684364 0.79 HTR1A (0.66) LMNAMAPK1HTR1ACHRM1DRD2
SCHEMBL683664 0.77 MAPK1 (0.56) LMNAMAPK1SMN1; SMN2RXFP1ADORA2B
SCHEMBL682817 0.74 LMNA (0.62) LMNAMAPK1DRD2SMN1; SMN2RXFP1
SCHEMBL684006 0.74 CHRM2 (0.72) LMNAMAPK1HTR1ACHRM1DRD2
SCHEMBL683615 0.72 ADORA2B (0.57) LMNAMAPK1HTR1ACHRM1DRD2
SCHEMBL683710 0.72 HTR2A (0.73) LMNAHTR1ACHRM1DRD2ADRA1D
SCHEMBL683655 0.72 HTR7 (0.77) LMNAMAPK1HTR1ASMN1; SMN2RXFP1
SCHEMBL684356 0.72 HTR7 (0.58) LMNAMAPK1SMN1; SMN2RXFP1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF LMNA 2155/4885MAPK1 470/4885HTR1A 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.